Gregory Renza Analyst Performance

Gregory Renza is a stock analyst at Royal Bank Of Canada in the medical sector, covering 18 publicly traded companies. Over the past year, Gregory Renza has issued 19 stock ratings, including buy and hold recommendations. While full access to Gregory Renza's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Gregory Renza's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Analyst Ranking

Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat

Average Return

00.00% 12-Month ROI

Success Rate

00.00% Profitable Ratings

Total Ratings

29 Last 6 Years

Buy Recommendations

75.86% 22 Buy Ratings

Companies Covered

18 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.0%	0 ratings
Buy	75.9%	22 ratings
Hold	24.1%	7 ratings
Sell	0.0%	0 ratings

Out of 29 total stock ratings issued by Gregory Renza at Royal Bank Of Canada, the majority (75.9%) have been Buy recommendations, followed by 24.1% Hold.

Best & Worst Calls

• Best Call

  0000.0%

  ARQL

  May 2019

  Subscribe to MarketBeat All Access to get analyst recommendation ROI.
• Worst Call

  000.0%

  AVTX

  Mar 2022

  Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	88.9% of companies on NASDAQ	16 companies
NYSE	11.1% of companies on NYSE	2 companies

Gregory Renza, an analyst at Royal Bank Of Canada, currently covers 18 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 18 companies	100.0%

Gregory Renza of Royal Bank Of Canada specializes in stock coverage within the Medical sector.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 12 companies	66.7%
PHARMACEUTICAL PREPARATIONS 3 companies	16.7%
MED - DRUGS 2 companies	11.1%
SURGICAL & MEDICAL INSTRUMENTS 1 company	5.6%

Gregory Renza's Ratings History at Royal Bank Of Canada

Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe

Start Date

End Date

All Ratings Strong Buy Buy Hold Sell Rating

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription

12-Month ROIUpgrade to All Access to use the All ROI Filter

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating	12-Month Price & ROI	Details
ACAD ACADIA Pharmaceuticals	5/19/2025	Reiterated Rating	$22.01	$26.00	Outperform	$0.00 00.00% ROI
ADCT ADC Therapeutics	5/15/2025	Reiterated Rating	$1.81	$8.00	Outperform	$0.00 00.00% ROI
INO Inovio Pharmaceuticals	5/14/2025	Reiterated Rating	$1.86	$5.00	Sector Perform	$0.00 00.00% ROI
EXEL Exelixis	5/14/2025	Reiterated Rating	$43.58	$40.00	Outperform	$0.00 00.00% ROI
JAZZ Jazz Pharmaceuticals	5/7/2025	Lower Price Target	$102.22	$172.00	Outperform	$0.00 00.00% ROI
BCYC Bicycle Therapeutics	5/2/2025	Lower Price Target	$9.43	$32.00	Outperform	$0.00 00.00% ROI
AMGN Amgen	5/2/2025	Lower Price Target	$279.88	$320.00	Outperform	$0.00 00.00% ROI
CGON CG Oncology	4/29/2025	Boost Price Target	$27.91	$68.00	Outperform	$0.00 00.00% ROI
SPRB Spruce Biosciences	4/16/2025	Lower Price Target	$9.62	$37.50	Sector Perform	$0.00 00.00% ROI
CATX Perspective Therapeutics	3/27/2025	Lower Price Target	$2.36	$15.00	Outperform	$0.00 00.00% ROI
CRMD CorMedix	3/26/2025	Reiterated Rating	$7.15	$12.00	Outperform	$0.00 00.00% ROI
VSTM Verastem	3/21/2025	Lower Price Target	$6.69	$14.00	Outperform	$0.00 00.00% ROI
INO Inovio Pharmaceuticals	3/19/2025	Lower Price Target	$2.03	$5.00	Sector Perform	$0.00 00.00% ROI
EXEL Exelixis	3/13/2025	Boost Price Target	$36.92	$40.00	Outperform	$0.00 00.00% ROI
JAZZ Jazz Pharmaceuticals	2/26/2025	Lower Price Target	$146.23	$178.00	Outperform	$0.00 00.00% ROI
NRIX Nurix Therapeutics	1/29/2025	Boost Price Target	$20.07	$27.00	Outperform	$0.00 00.00% ROI
AMGN Amgen	1/24/2025	Reiterated Rating	$275.63	$324.00	Outperform	$0.00 00.00% ROI
IDYA IDEAYA Biosciences	1/15/2025	Reiterated Rating	$23.64	$61.00	Outperform	$0.00 00.00% ROI
CATX Perspective Therapeutics	1/14/2025	Reiterated Rating	$3.22	$16.00	Outperform	$0.00 00.00% ROI

Stock Forecasts and Research Tools

Sign in to your free account to enjoy these benefits

• In-depth profiles and analysis for 20,000 public companies.
• Real-time analyst ratings, insider transactions, earnings data, and more.
• Our daily ratings and market update email newsletter.

Sign in to your free account to enjoy all that MarketBeat has to offer.

• Sign In
• Create Account

Your Email Address:

Email Address Required

Your Password:

Password Required

Log In

---

or

Sign in with Facebook Sign in with Google

Forgot your password?

Your Email Address:

Please enter your email address.

Please enter a valid email address

Choose a Password:

Please enter your password.

Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character.

Create My Account (Free)

---

or

Sign in with Facebook Sign in with Google

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.